SYSADOASymptomatic Slow Acting Drugs in Osteo-Arthritis
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Findings reported in the 90s decade about articular cartilage, its metabolic activity, and regenerative capacity [29, 30] have led to the proposal of chondromodulating and/or chondroprotective substances, which constitute the group of slow-acting drugs or SYSADOA, including cartilaginous matrix precursors (glucosamine, chondroitin, and hyaluronic acid) and cytokine modulators (diacerein and metalloprotease inhibitors) [24].
As their name implies, SYSADOA offer a slow onset of relief-approximately 2 weeks--and their effects may remain active for as long as 2 months after their omission [61].
I SYSADOA (glucosamina solfato, condroitin solfato, estratti di soia ed avocado, acido ialuronico) hanno effetti sintomatici e bassa tossicita, ma restano da definire i loro effetti strutturali, i pazienti piu idonei da trattare, e la convenienza farmacoeconomica del trattamento.
The double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) was conducted in France, Germany, Poland and Spain, evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score [greater than or equal to] 301; 0-500 scale).